Tandem Diabetes Care, Inc. is a healthcare company based in the United States of America that specializes in designing and manufacturing durable insulin pumps for diabetes patients. With a high ESG risk rating score of 34.8, the company is focused on sustainability and governance practices. Tandem Diabetes has been a key player in the market since 2012, with their flagship product being the t:slim X2 device. They have recently launched the smaller Mobi pump and are working on a tubeless pump. Majority of their revenue comes from the US market, with the rest from other developed nations. The company's sales are mainly driven by insulin pumps and disposable infusion sets.